Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05282550 · ClinicalTrials.gov registry record · Phase 2
Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone
A Phase 2 study of Sleep Disturbance and AMCI - Amnestic Mild Cognitive Impairment, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05282550 is a Phase 2 study of Sleep Disturbance and AMCI - Amnestic Mild Cognitive Impairment that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 100 participants, below the 176-participant average among 56 other Sleep Disturbance trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05282550, a Phase 2 study of Sleep Disturbance and AMCI - Amnestic Mild Cognitive Impairment, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Trazodone
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05282550
The ClinicalTrials.gov registry entry for NCT05282550 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 176-participant average among 56 other Sleep Disturbance trials with a reported enrollment target (43% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sleep Disturbance appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05282550 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05282550 about?
NCT05282550 is a clinical study titled "Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone". To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).
What is the current status of trial NCT05282550?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-02-02. Estimated completion is 2028-06-30.
What conditions does trial NCT05282550 study?
This clinical trial studies the following conditions: Sleep Disturbance, AMCI - Amnestic Mild Cognitive Impairment.
What interventions are being tested in trial NCT05282550?
The interventions under investigation include: Placebo (DRUG), Trazodone (DRUG).
Who is sponsoring clinical trial NCT05282550?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05282550 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sleep Disturbance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk
RECRUITING · Phase 2
-
RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
ACTIVE NOT RECRUITING · Phase 2
-
RECOVER-SLEEP: Platform Protocol
COMPLETED · Phase 2
-
Clinical Benefits of a Novel Sleep-focused Mind-body Program on Gulf War Illness (GWI) Symptoms
COMPLETED · Phase 2
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
Sleep and Central Auditory Processing Disorder in Autism Spectrum Disorder
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.